It refers to a combination of pharmacology, including a PD-1 diagonal and a GITR dying person, who are useful in the treatment of immune disorders and spread, especially in advanced countries. PD-1 target country was selected from bms-936558 (nivolumab).Mk-3475 (pembrolizumab) and mpd3280 a (atezolizumab). GITR drug kingpin is selected from (I) an antibody whose heavy chain has a variable number 67, 69, 71, 73, 75, 77, 79, 81, 83 and 85 in the international transaction log； and (III) tx518 and tx385, which have no. 68, 70, 72, 74, 76, 78, 80, 82, 84, 86 and 88. It also refers to pharmacology composers, including a combination of a pd-1-type counterpart and a GITR type playwright, mixed with an acceptable vehicle or former pharmacologist.SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA PD–1 Y UN AGONISTA GITR, UTILES EN EL TRATAMIENTO DE TRASTORNOS INMUNITARIOS Y PROLIFERATIVOS, ESPECIALMENTE DE TUMORES EN ESTADOS AVANZADOS. EL ANTAGONISTA PD–1 SE SELECCIONA ENTRE BMS–936558 (NIVOLUMAB), MK–3475 (PEMBROLIZUMAB) Y MPDL3280A (ATEZOLIZUMAB). EL AGONISTA GITR SE SELECCIONA ENTRE (I) UN ANTICUERPO QUE TIENE UNA CADENA PESADA VARIABLE DE LAS SEC ID NOS: 67, 69, 71, 73, 75, 77, 79, 81, 83 Y 85； Y UNA CADENA LIGERA VARIABLE DE LAS SEC ID NOS: 68, 70, 72, 74, 76, 78, 80, 82, 84, 86 Y 88； (II) TRX518； Y (III) TRX385. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LA COMBINACION DE UN ANTAGONISTA PD–1 JUNTO CON UN AGONISTA GITR, EN MEZCLA CON UN VEHICULO O EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE.
